Incyte Corp. (INCY)
121.47
-1.81
(-1.47%)
USD |
NASDAQ |
Sep 11, 16:00
121.75
+0.28
(+0.23%)
After-Hours: 20:00
Incyte Enterprise Value : 19.92B for Sept. 11, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 11, 2026 | 19.92B |
| September 10, 2026 | 20.28B |
| September 09, 2026 | 20.83B |
| September 08, 2026 | 20.50B |
| September 04, 2026 | 20.98B |
| September 03, 2026 | 21.23B |
| September 02, 2026 | 21.39B |
| September 01, 2026 | 20.63B |
| August 31, 2026 | 20.27B |
| August 28, 2026 | 20.50B |
| August 27, 2026 | 21.18B |
| August 26, 2026 | 21.25B |
| August 25, 2026 | 21.57B |
| August 24, 2026 | 21.22B |
| August 21, 2026 | 21.19B |
| August 20, 2026 | 21.07B |
| August 19, 2026 | 21.32B |
| August 18, 2026 | 20.32B |
| August 17, 2026 | 20.32B |
| August 14, 2026 | 19.65B |
| August 13, 2026 | 19.72B |
| August 12, 2026 | 19.77B |
| August 11, 2026 | 19.83B |
| August 10, 2026 | 19.93B |
| August 07, 2026 | 19.73B |
| Date | Value |
|---|---|
| August 06, 2026 | 19.29B |
| August 05, 2026 | 19.58B |
| August 04, 2026 | 19.74B |
| August 03, 2026 | 19.30B |
| July 31, 2026 | 19.52B |
| July 30, 2026 | 20.22B |
| July 29, 2026 | 21.05B |
| July 28, 2026 | 21.62B |
| July 27, 2026 | 19.39B |
| July 24, 2026 | 19.15B |
| July 23, 2026 | 18.95B |
| July 22, 2026 | 18.77B |
| July 21, 2026 | 19.10B |
| July 20, 2026 | 18.75B |
| July 17, 2026 | 19.07B |
| July 16, 2026 | 18.95B |
| July 15, 2026 | 18.63B |
| July 14, 2026 | 18.59B |
| July 13, 2026 | 18.46B |
| July 10, 2026 | 18.96B |
| July 09, 2026 | 19.32B |
| July 08, 2026 | 19.07B |
| July 07, 2026 | 19.23B |
| July 06, 2026 | 18.74B |
| July 02, 2026 | 18.99B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Mirum Pharmaceuticals, Inc. | 6.685B |
| Regeneron Pharmaceuticals, Inc. | 75.51B |
| AbbVie, Inc. | 518.65B |
| Biogen, Inc. | 39.14B |
| Eli Lilly & Co. | 1.096T |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 585.60M |
| Revenue (Quarterly) | 1.674B |
| Total Expenses (Quarterly) | 1.088B |
| EPS Diluted (Quarterly) | 2.812 |
| Gross Profit Margin (Quarterly) | 92.57% |
| Profit Margin (Quarterly) | 34.98% |
| Earnings Yield | 6.46% |
| Operating Earnings Yield | 7.38% |
| Normalized Earnings Yield | 6.561 |